Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies.

Q1 Medicine Pathogens and Immunity Pub Date : 2022-06-24 eCollection Date: 2022-01-01 DOI:10.20411/pai.v7i1.518

Michael J Peluso, Khamal Anglin, Matthew S Durstenfeld, Jeffrey N Martin, J Daniel Kelly, Priscilla Y Hsue, Timothy J Henrich, Steven G Deeks

{"title":"Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies.","authors":"Michael J Peluso, Khamal Anglin, Matthew S Durstenfeld, Jeffrey N Martin, J Daniel Kelly, Priscilla Y Hsue, Timothy J Henrich, Steven G Deeks","doi":"10.20411/pai.v7i1.518","DOIUrl":null,"url":null,"abstract":"Background: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and treatment on the development and persistence of Long COVID have intensified.Methods: We report 4 sequential cases from a post-COVID cohort study demonstrating variability in outcomes following differentially timed nirmatrelvir therapy, received as part of clinical care.Results: In the first case, the participant experienced symptomatic rebound and developed Long COVID despite early initiation of antiviral therapy. In the next 2 cases, participants reported improvement in persistent COVID symptoms when nirmatrelvir was taken 25 and 60 days following initial symptom onset. In the final case, an individual with presumed Long COVID for 2 years reported substantial improvement in chronic symptoms when taking nirmatrelvir following SARS-CoV-2 re-infection.Conclusions: These anecdotes suggest that systematic study of antiviral therapy for Long COVID is warranted.","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"7 1","pages":"95-103"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254867/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20411/pai.v7i1.518","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and treatment on the development and persistence of Long COVID have intensified.

Methods: We report 4 sequential cases from a post-COVID cohort study demonstrating variability in outcomes following differentially timed nirmatrelvir therapy, received as part of clinical care.

Results: In the first case, the participant experienced symptomatic rebound and developed Long COVID despite early initiation of antiviral therapy. In the next 2 cases, participants reported improvement in persistent COVID symptoms when nirmatrelvir was taken 25 and 60 days following initial symptom onset. In the final case, an individual with presumed Long COVID for 2 years reported substantial improvement in chronic symptoms when taking nirmatrelvir following SARS-CoV-2 re-infection.

Conclusions: These anecdotes suggest that systematic study of antiviral therapy for Long COVID is warranted.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

口服 Nirmatrelvir 对长期 COVID 症状的影响：4 个病例和系统研究的理由。

背景：为了解SARS-CoV-2变异体、疫苗状态和治疗对长COVID的发展和持续的影响，人们加大了努力：方法：我们报告了长COVID后队列研究中的4个连续病例，这些病例显示了在接受不同时间的尼尔马特韦治疗（作为临床治疗的一部分）后的结果变化：在第一个病例中，尽管及早开始了抗病毒治疗，但参与者还是出现了症状反弹，并发展为长COVID。在接下来的两个病例中，参与者报告说，在最初症状出现 25 天和 60 天后服用尼尔马特韦，持续性 COVID 症状有所改善。在最后一个病例中，一名推测患有长COVID达2年之久的患者报告说，在SARS-CoV-2再感染后服用尼尔马特韦后，慢性症状得到了很大改善：这些轶事表明，有必要对长COVID的抗病毒治疗进行系统研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊